This HTML5 document contains 92 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/chemspider/
n13http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/wikipedia/
n32http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/pdb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/pubchem-compound/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/mesh/
n30http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/kegg-drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/iuphar/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/guide-to-pharmacology/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00145/identifier/national-drug-code-directory/
n31http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00145
rdf:type
n3:Drug
n3:description
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem]
n3:dosage
n16:271B4B16-363D-11E5-9242-09173F13E4C5 n16:271B4B17-363D-11E5-9242-09173F13E4C5
n3:group
nutraceutical approved
n3:indication
Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.
n3:manufacturer
n14:271B4B0F-363D-11E5-9242-09173F13E4C5 n14:271B4B10-363D-11E5-9242-09173F13E4C5 n14:271B4B11-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00145 n32:DB00145
dcterms:title
Glycine
adms:identifier
n6:Glycine n17:0338-0289-47 n18:GLY n19:C00037 n20:D00011 n21:46508219 n22:PA449789 n23:750 n24:15428 n25:727 n26:727 n27:730 n28:DB00145
n3:mechanismOfAction
In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. <br/>Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS.
n3:packager
n14:271B4B0D-363D-11E5-9242-09173F13E4C5 n14:271B4B0E-363D-11E5-9242-09173F13E4C5 n14:271B4B0B-363D-11E5-9242-09173F13E4C5 n14:271B4B0C-363D-11E5-9242-09173F13E4C5 n14:271B4B09-363D-11E5-9242-09173F13E4C5 n14:271B4B0A-363D-11E5-9242-09173F13E4C5 n14:271B4B07-363D-11E5-9242-09173F13E4C5 n14:271B4B08-363D-11E5-9242-09173F13E4C5
n3:synonym
Hgly Glycine Glycocoll H2N-CH2-COOH Glykokoll Leimzucker Glycin Aminoethanoic acid G Aminoessigsaeure Aminoacetic acid Gly Glyzin
n3:toxicity
ORL-RAT LD<sub>50</sub> 7930 mg/kg, SCU-RAT LD<sub>50</sub> 5200 mg/kg, IVN-RAT LD<sub>50</sub> 2600 mg/kg, ORL-MUS LD<sub>50</sub> 4920 mg/kg; Doses of 1 gram daily are very well tolerated. Mild gastrointestinal symptoms are infrequently noted. In one study doses of 90 grams daily were also well tole.
n12:hasAHFSCode
n13:40-36-00
n3:synthesisReference
Koichi Niimura, Takako Kawabe, Takao Ando, Kenichi Saito, "Phenylalanine-glycine compounds having anti-tumor activity, process for preparation thereof, and pharmaceutical composition containing said compounds." U.S. Patent US5411964, issued August, 1908.
n9:hasConcept
n10:M0009451
foaf:page
n30:gly_0127.shtml
n3:IUPAC-Name
n4:271B4B1C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B22-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B21-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B1E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B1F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B20-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B1A-363D-11E5-9242-09173F13E4C5 n4:271B4B32-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B1B-363D-11E5-9242-09173F13E4C5 n4:271B4B18-363D-11E5-9242-09173F13E4C5 n4:271B4B34-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B19-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4B35-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n31:B05CX03
n3:H-Bond-Acceptor-Count
n4:271B4B28-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B29-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B23-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B24-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B26-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B25-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B27-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed from the small intestine via an active transport mechanism.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56-40-6
n3:category
n3:containedIn
n15:271B4B14-363D-11E5-9242-09173F13E4C5 n15:271B4B15-363D-11E5-9242-09173F13E4C5 n15:271B4B12-363D-11E5-9242-09173F13E4C5 n15:271B4B13-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B2E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B30-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B31-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B33-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B2D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B2C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B2F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B1D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B2A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B2B-363D-11E5-9242-09173F13E4C5